PMID- 27376688
OWN - NLM
STAT- MEDLINE
DCOM- 20170531
LR  - 20220410
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 46
IP  - 8
DP  - 2016 Aug
TI  - Optimisation of triple therapy for patients with chronic hepatitis C: a 
      systematic review.
PG  - 737-48
LID - 10.1111/eci.12656 [doi]
AB  - BACKGROUND: Triple therapy with Pegylated-Interferon alpha (PEG-IFNalpha)/Ribavirin (RBV) 
      and Boceprevir (Boc) or Telaprevir (Tel) significantly improved sustained 
      virological response (SVR) rates for patients with genotype 1 HCV infection 
      compared to PEG-IFNalpha/RBV alone (dual therapy). However, less is known about 
      factors associated with rates of SVR and of adverse events (AEs). MATERIAL AND 
      METHODS: The aim of this systematic review was to evaluate the evidence regarding 
      the factors affecting response and rate of AEs associated with triple therapy. We 
      performed systematic electronic searches in Medline, Embase, Scopus and Central 
      as well as a list of reference literature. We included randomised controlled 
      trials examining triple therapy compared with dual therapy and reporting data 
      according to patients features and about AEs. Odds ratios (OR) were pooled using 
      either fixed or random effect model, as appropriate. RESULTS: We included data 
      from 14 studies. Treatment with triple therapy increased SVR rate compared to 
      dual therapy especially in patients previously treated with PEG-IFNalpha/RBV and with 
      increased pretreatment alanine aminotransferase (ALT) levels. Higher rate of 
      serious AEs and treatment discontinuation due to AEs was also observed 
      particularly in treatment-experienced patients. CONCLUSIONS: The present study 
      shows how improved results of triple therapy are mainly observed in some 
      patients' subsets and are accompanied by increased risk of AEs compared to dual 
      therapy. These results might be useful for optimising treatment of chronic 
      hepatitis C when IFN-free regimens are unavailable.
CI  - (c) 2016 Stichting European Society for Clinical Investigation Journal Foundation.
FAU - Pecoraro, Valentina
AU  - Pecoraro V
AD  - Clinical Pathology - Toxicology, Ospedale Civile Sant'Agostino Estense, Modena, 
      Italy.
FAU - Cariani, Elisabetta
AU  - Cariani E
AD  - Clinical Pathology - Toxicology, Ospedale Civile Sant'Agostino Estense, Modena, 
      Italy.
FAU - Villa, Erica
AU  - Villa E
AD  - Division of Gastroenterology, AOU Modena, Modena, Italy.
FAU - Trenti, Tommaso
AU  - Trenti T
AD  - Clinical Pathology - Toxicology, Ospedale Civile Sant'Agostino Estense, Modena, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - 89BT58KELH 
      (N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide)
RN  - 9DLQ4CIU6V (Proline)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Adult
MH  - Antiviral Agents/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Interferon-alpha/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/*therapeutic use
MH  - Proline/*analogs & derivatives/therapeutic use
MH  - Recombinant Proteins/therapeutic use
MH  - Ribavirin/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Boceprevir
OT  - Telaprevir
OT  - hepatitis C
OT  - meta-analysis
EDAT- 2016/07/05 06:00
MHDA- 2017/06/01 06:00
CRDT- 2016/07/05 06:00
PHST- 2016/05/05 00:00 [received]
PHST- 2016/02/11 00:00 [accepted]
PHST- 2016/07/05 06:00 [entrez]
PHST- 2016/07/05 06:00 [pubmed]
PHST- 2017/06/01 06:00 [medline]
AID - 10.1111/eci.12656 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2016 Aug;46(8):737-48. doi: 10.1111/eci.12656.